Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
J Clin Gastroenterol ; 58(5): 487-493, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-37339277

RESUMO

GOALS: This study aims to investigate associated mortality with inpatient endoscopic retrograde cholangiopancreatography (ERCP) with and without resistant infections. The co-primary objective compares frequencies of inpatient ERCP with resistant infections to overall hospitalizations with resistant infections. BACKGROUND: The risks of inpatient antibiotic-resistant organisms are known, but the associated mortality for inpatient ERCP is unknown. We aim to use a national database of hospitalizations and procedures to understand trends and mortality for patients with antibiotic-resistant infections during inpatient ERCP. STUDY: The largest publicly available all-payer inpatient database in the United States (National Inpatient Sample) was used to identify hospitalizations associated with ERCPs and antibiotic-resistant infections for MRSA, VRE, ESBL, and MDRO. National estimates were generated, frequencies were compared across years, and multivariate regression for mortality was performed. RESULTS: From 2017 to 2020, national weighted estimates of 835,540 inpatient ERCPs were generated, and 11,440 ERCPs had coincident resistant infections. Overall resistant infection, MRSA, VRE, and MDRO identified at the same hospitalization of inpatient ERCPs were associated with higher mortality (OR CI(95%): Overall: 2.2(1.77-2.88), MRSA: 1.90 (1.34-2.69), VRE: 3.53 (2.16-5.76), and MDRO: 2.52 (1.39-4.55)). While overall hospitalizations with resistant infections have been decreasing annually, there has been a yearly increase in admissions requiring ERCPs with simultaneous resistant infections ( P =0.001-0.013), as well as infections with VRE, ESBL, and MDRO ( P =0.001-0.016). Required Research Practices for Studies Using the NIS scoring was 0, or the most optimal. CONCLUSIONS: Inpatient ERCPs have increasing coincident resistant infections and are associated with higher mortality. These rising infections during ERCP highlight the importance of endoscopy suite protocols and endoscopic infection control devices.


Assuntos
Colangiopancreatografia Retrógrada Endoscópica , Pacientes Internados , Humanos , Estados Unidos/epidemiologia , Colangiopancreatografia Retrógrada Endoscópica/efeitos adversos , Estudos Transversais , Antibacterianos/uso terapêutico , Estudos de Coortes , Estudos Retrospectivos
2.
Case Rep Gastroenterol ; 16(1): 148-153, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35528771

RESUMO

A pancreaticopleural fistula (PPF) is a rare complication of chronic pancreatitis secondary to a pancreatic pseudocyst or any disruption of the main pancreatic duct. It commonly presents as a recurrent left-sided pleural effusion after multiple thoracentesis. We present a rare case of a 41-year-old woman with numerous flares of chronic pancreatitis presenting with large bilateral serosanguinous pleural effusions and trapped lung secondary to a PPF. To our knowledge, this is the first documented case of a PPF leading to bilateral pleural effusions resulting in a trapped lung.

3.
J Natl Med Assoc ; 114(4): 426-429, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35525822

RESUMO

BACKGROUND: Gastrointestinal cancers account for a significant burden of cancers in the United States. We sought to measure relative incidence of and mortality from the five most common gastrointestinal malignancies by race and ethnicity. METHODS: We used data from the National Cancer Institute Surveillance, Epidemiology, and End Results Cancer Registry and the National Center for Health Statistics to calculate incidence and mortality rates for colorectal, pancreatic, liver, esophageal, and gastric cancer from 2013 to 2017 (incidence) and 2014 to 2018 (mortality). We then calculated incidence and mortality rate ratios, comparing each racial/ethnic group (non-Hispanic Black, non-Hispanic Asian/Pacific Islander, non-Hispanic American Indian/Alaska Native, and Hispanic) to non-Hispanic White. RESULTS: Colorectal cancer had highest overall incidence and mortality. When compared to non-Hispanic White individuals, all other racial/ethnic groups had significantly higher incidence of liver and gastric cancer but lower incidence of esophageal cancer. Non-Hispanic Black individuals had higher incidence of colorectal and pancreatic cancer than non-Hispanic White individuals, while Hispanic and non-Hispanic Asian/Pacific Island individuals had lower incidence of these two cancers compared to non-Hispanic White individuals. Disparity patterns were similar for mortality. CONCLUSIONS: Liver and gastric cancer have the greatest differences in incidence and mortality by race/ethnicity. Non-Hispanic Black individuals carry the highest burden of gastrointestinal malignancies overall.


Assuntos
Neoplasias Colorretais , Neoplasias Gástricas , Etnicidade , Humanos , Incidência , Grupos Raciais , Neoplasias Gástricas/epidemiologia , Estados Unidos/epidemiologia
4.
Hepatol Commun ; 5(3): 371-386, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33681673

RESUMO

New therapies offer hope for a cure to millions of persons living with hepatitis C virus (HCV) infection. HCV elimination is a global goal that will be difficult to achieve using the traditional paradigms of diagnosis and care. The current standard has evolved toward universal HCV screening and treatment, to achieve elimination goals. There are several steps between HCV diagnosis and cure with major barriers along the way. Innovative models of care can address barriers to better serve hardly reached populations and scale national efforts in the United States and abroad. Herein, we highlight innovative models of HCV care that aid in our progress toward HCV elimination.


Assuntos
Erradicação de Doenças/organização & administração , Acessibilidade aos Serviços de Saúde , Hepatite C/prevenção & controle , Programas de Rastreamento/organização & administração , Inovação Organizacional , Antivirais/uso terapêutico , Erradicação de Doenças/métodos , Hepacivirus , Hepatite C/epidemiologia , Humanos , Programas de Rastreamento/métodos
5.
Dig Dis Sci ; 66(4): 1175-1188, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-32451757

RESUMO

BACKGROUND AND AIMS: A network meta-analysis showed that low-cost optimization of existing resources was as effective as distal add-on devices in increasing adenoma detection rate (ADR). We assessed the impacts of water exchange (WE), Endocuff, and cap colonoscopy on ADR and advanced adenoma detection rate (AADR). We hypothesized that WE may be superior at improving ADR and AADR. METHODS: The literature was searched for all randomized controlled trials (RCTs) that reported ADR as an outcome and included the keywords colonoscopy, and water exchange, Endocuff, or cap. We performed traditional network meta-analyses with random effect models comparing ADR and AADR of each method using air insufflation (AI) as the control and reported the odds ratios with 95% confidence interval. Performances were ranked based on P-score. RESULTS: Twenty-one RCTs met inclusion criteria. Fourteen RCTs also reported AADR. Both WE [1.46 (1.20-1.76)] and Endocuff [1.39 (1.17-1.66)] significantly increase ADR, while cap has no impact on ADR [1.00 (0.82-1.22)]. P-scores for WE (0.88), Endocuff (0.79), cap (0.17), and AI (0.17) suggest WE has the highest ADR. WE [1.38 (1.12-1.70)], but not Endocuff [0.96 (0.76-1.21)] or cap [1.06 (0.85-1.32)], significantly increases AADR. P-scores for WE (0.98), cap (0.50), AI (0.31), and Endocuff (0.21) suggest WE is more effective at increasing AADR. The results did not change after adjusting for age, proportion of males, and withdrawal time. CONCLUSION: WE may be the modality of choice to maximally improve ADR and AADR.


Assuntos
Adenoma/diagnóstico por imagem , Adenoma/cirurgia , Colonoscopia/métodos , Metanálise em Rede , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Água/administração & dosagem , Humanos , Estudos Prospectivos
7.
Hepatol Commun ; 4(6): 825-833, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32490319

RESUMO

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Society guidelines recommend surveillance with abdominal ultrasound with or without serum alpha-fetoprotein every 6 months for adults at increased risk of developing HCC. However, adherence is often suboptimal. We assessed the feasibility of a coordinated telephone outreach program for unscreened patients with cirrhosis within the Veteran's Affairs (VA) health care system. Using a patient care dashboard of advanced chronic liver disease in the VA Greater Los Angeles Healthcare System, we identified veterans with a diagnosis of cirrhosis, a platelet count ≤ 150,000/uL, and no documented HCC surveillance in the previous 8 months. Eligible veterans received a telephone call from a patient navigator to describe the risks and benefits of HCC surveillance. Orders for an abdominal ultrasound and alpha-fetoprotein were placed for veterans who agreed to surveillance. Veterans who were not reached by telephone received an informational letter by mail to encourage participation. Of the 129 veterans who met the eligibility criteria, most were male (96.9%). The most common etiology for cirrhosis was hepatitis C (64.3%), and most of the patients had compensated cirrhosis (68.2%). The patient navigators reached 32.5% of patients by phone. Patients in each group were similar across clinical and demographic characteristics. Patients who were called were more likely to undergo surveillance (adjusted odds ratio = 2.56, 95% confidence interval: 1.03-6.33). Most of the patients (72.1%) completed abdominal imaging when reached by phone. Conclusion: Targeted outreach increased uptake of HCC surveillance among patients with cirrhosis in a large, integrated, VA health care system.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...